Ciforadenant Drug Asset Due Diligence Report 2026

This Ciforadenant Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Ciforadenant can convert its Small molecule drug profile and A2aR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Ciforadenant (query alias: Ciforadenant)
Modality / target	Small molecule drug; A2aR; A2aR antagonists
Highest global status	Phase 2
Originator	Ligand UK Ltd.
Active developers	The University of Texas MD Anderson Cancer Center, Corvus Pharmaceuticals, Inc.

The MCP disease footprint includes Renal Cell Carcinoma, Advanced Renal Cell Carcinoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05501054	Phase 1/2	Active, not recruiting	50	Primary endpoint not disclosed in English source
NCT04280328	Phase 1	Completed	7	Primary endpoint not disclosed in English source
NCT03454451	Phase 1	Completed	117	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

2596MO - Phase Ib/II trial of ipilimumab, nivolumab, and ciforadenant (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma (RCC), a kidney cancer research consortium study

Phase 1/2; n=50; evaluation: Negative. Reported fields: >50% tumor shrinkage = 32.0 % ( 20 - 45)

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

Phase 1/2; n=35; evaluation: Positive. Reported fields: PSA-RR(reductions >30%) = 9 % ; PSA-RR(reductions >30%) = 21 %

1315P - Phase Ib/II open-label, randomised evaluation of atezolizumab (atezo) + CPI-444 vs docetaxel as second/third-line therapy in MORPHEUS-NSCLC (non-small cell lung cancer)

Phase 2; n=not disclosed; evaluation: Negative. Reported fields: ORR = 6.7 % ; ORR = 21.4 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Ciforadenant addresses Renal Cell Carcinoma, Advanced Renal Cell Carcinoma. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 3 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2020-10-05	Corvus Pharmaceuticals Announces Co-Founding of Angel Pharmaceuticals in China	Phase 2	Financial terms not disclosed
Not disclosed	Ligand Announces the Close of its Acquisition of Vernalis	Phase 1	US$42.3M stated total
2015-02-01	Vernalis Announces Corvus Pharmaceuticals, Inc. as Its Worldwide Licensee for Their Adenosine Antagonist Program	Phase 1/2	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Adenosine a2a receptor antagonists to treat REM sleep behavior disorder and prevent synucleinopathies”. The milestone feed surfaced a patent-application signal described as “Cyclin-dependent kinase (CDK) 12 and/or CDK13 inhibitor combinations and uses thereof”. The milestone feed surfaced a patent-application signal described as “Combinations treatments of diacylglycerol kinase (DGK) alpha inhibitors and other therapies”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO